Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)

Running, not enrolling · Phase 1/Phase 2

Conditions studied: Gaucher Disease, Type 1

In brief

This is a multicenter, long-term, follow-up trial of participants with Gaucher disease type 1 who received FLT201 treatment in a preceding clinical trial. Participants will be followed for 5 years post-treatment.

Key facts

Study ID

NCT06545136

Run by

Spur Therapeutics

People needed

75

Starts

2024-05-13

Expected to finish

2029-05-01

Last updated by the study team

2025-11-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1. Participants who have previously received FLT201 (including those who may have required recommencement or initiation of ERT/substrate reduction therapy [SRT]).
• 2. Participants able to give full informed consent and able to comply with all requirements of the trial.

You may not qualify if…

• n/a

Where it is running

• Lysosomal Rare Disorders Research and Treatment Center — Fairfax, Virginia, United States
• Hospital de Clinicas de Porto Alegre (HCPA) — Porto Alegre, Brazil
• Hospital Quironsalud Zaragoza — Zaragoza, Spain
• Salford Royal Hospital — Salford, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.